-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3954 Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Hematology Disease Topics & Pathways:
Biological, Adults, Clinical Research, Diseases, Therapies, Registries, Myeloid Malignancies, Study Population, Transplantation
Monday, December 13, 2021, 6:00 PM-8:00 PM

Guillermo Ortí, MD, PhD1*, Luuk Gras Sr.2*, Nienke Zinger3*, Aleksandr D. Kulagin4*, Jennifer Byrne5*, Jane F Apperley, FRCP, FRCPath, MB6, Kazimierz Halaburda7*, Igor Wolfgang Blau, MD8*, Andrew Clark9*, Nicolaus Kröger, MD10*, Laimonas Griskevicius11*, Kristina Carlson, MD, PhD12, Matthew P. Collin, MD, PhD13,14, Adrian Bloor, MD, PhD, FRCP, FRCPath15*, Emanuele Angelucci16, Didier Blaise17, Mahmoud Aljurf18, Lucia Lopez Corral, MD, PhD19*, Achilles Anagnostopoulos20, Yves Beguin, MD, PhD21, Tomasz Wrobel, MD, PhD22, Luigi Rigacci, lrigacci@scamilloforlanini.rm.it23*, Patrick John Hayden, BA24, Yves Chalandon, MD25 and Ibrahim Yakoub-Agha26

1Hospital Universitari Vall d’Hebron, Barcelona, Spain
2EBMT Statistical Unit, Leiden, Netherlands
3EBMT Data Office, Leiden, Netherlands
4Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, First Pavlov State Medical University of St. Petersburg, St Petersburg, Russian Federation
5Nottingham City Hospital, Nottingham, United Kingdom
6Centre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College, London, United Kingdom
7Institute of Hematology and Transfusion Medicine, Warsaw, Poland
8Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
9Beatson , West of Scotland Cancer Centre, Glasgow, GBR
10University Hospital Eppendorf, Hamburg, Germany
11Vilnius University Hospital Santariskiu Clinics, Vilnius, Na, LTU
12Uppsala University Hospital, Uppsala, Uppsala Laen, Sweden
13Northern Centre for Bone Marrow Transplantation, Newcastle Upon Tyne, UK, Newcastle Upon Tyne, United Kingdom
14Adult HSCT unit, Northern Centre for Bone Marrow Transplantation, Newcastle Upon Tyne, United Kingdom
15Adult Leukaemia and Bone Marrow Transplant Unit, The Christie Hospital NHS Foundation Trust, University of Manchester, Manchester, United Kingdom
16Department of Hematology II, San Martino University Hospital, Genoa, Italy
17Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France
18Oncology, Section of Adult Haematolgy/BMT, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
19Department of Hematology, Hospital Clínico Universitario de Salamanca, IBSAL, Salamanca, Spain
20Hematology Department – HCT Unit, George Papanicolaou Hospital, Thessaloniki, Greece
21CHU de Liège, University of Liège, Liege, Belgium
22Wrocław Medical University, Wrocław, Poland
23Dept. of hematology and BMT, Ospedale S. Camillo-Forlanini, Roma, Italy
24Department of Haematology, Trinity College Dublin, St.James Hospital, Dublin, Ireland
25Geneva University Hospitals, Geneva, Switzerland
26Centre Hospitalier Universitaire de Lille LIRIC, INSERM U1286, Université de Lille, Lille, France


Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment option in patients with advanced Chronic Myeloid Leukemia (CML) who have disease resistant to tyrosine kinase inhibitors (TKI) or who cannot tolerate these agents. In the absence of a matched sibling donor (MSD), the use of an unrelated donor (UD) is recommended; however, this approach is associated with a higher incidence of both graft-versus-host disease (GvHD) and non-relapse mortality (NRM). Post-transplant cyclophosphamide (PTCy) has been found to result in similar rates of GvHD-free, relapse-free survival (GRFS) in allo-HCT using UD, haploidentical donors (HD) and MSD across a range of haematological malignancies. However, the role of PTCy in allo-HCT using UD and HD in CML is unknown. We here report an observational, retrospective, comparative study on the role of PTCy in UD and HD in CML patients undergoing allo-HCT.


Inclusion criteria were age ≥ 18 years, diagnosis of CML, first AlloHCT from 2012 to 2019, and UD and HD. The main endpoints of the study were to compare the one-year GRFS of allo-HCT using UD with standard GvHD prophylaxis (SP), PTCy UD and PTCy HD. Secondary endpoints were 3-year OS, 3-year PFS, 3-year NRM, 3-year RI, Day +100 acute GvHD (aGvHD) and one-year chronic GvHD (cGvHD). The Kaplan-Meier estimator and log-rank test were used for GRFS, OS and PFS, and the crude cumulative incidence estimator and Gray’s test were used for competing events (RI/NRM, aGvHD/death before aGvHD and cGvHD/death before cGvHD). Cox proportional hazard regression was used in multivariable analyses (MVA) using patients with complete data with cause-specific models for competing risk outcomes.


A total of 1,341 CML patients treated in EBMT centers were included. 1,094 patients received allo-HCT from SP UD, 113 from PTCy UD and 134 from PTCy HD. 61% and 54% of patients received an allo-HCT from matched UD in the SP UD and PTCy UD cohort, respectively. SP UD GvHD prophylaxis was calcineurin inhibitor-based in 88% of patients; some form of T-cell depletion was used in 82%, 19% and 9% in the SP UD, PTCy UD, and PTCy HD cohorts, respectively. Further transplant and patient details can be found in Table 1.

The median follow-up was 34.9 (IQR 13.2-61.2) months. One-year GRFS was comparable in the three cohorts: 56%, 53% and 48% in SP UD, PTCy UD, and PTCy HD, respectively (log-rank p=0.30). There was no significant difference in the cumulative incidence of aGvHD at D+100 (Gray’s test p=0.10) and one-year cGvHD (p=0.40) among cohorts. Conversely, the 3-year relapse incidence (RI) was significantly lower in the SP UD cohort (26%), compared to the PTCy UD (35%) and PTCy HD (34%) cohorts (Gray’s test p=0.03) and the 3-year progression-free survival (PFS) was 53% vs 47% vs 45% in the SP UD, PTCy UD and PTCy HD cohorts, respectively (log-rank p=0.05). 3-year NRM was similar among cohorts 20% vs 18% vs 21% in SP UD, PTCy UD and PTCy HD, respectively (Gray’s test p=0.80) and the three cohorts had a similar 3-year OS (64%, 60% and 59% in SP UD, PTCy UD and PTCy UD, respectively) (p=0.50).

In total 902 patients (68%) had complete data. In MVA, higher age (HR per 10 year increase in age 1.24, 95% CI 1.06-1.45, p=0.007) and high HCT-CI (HR high vs. low 2.43, 1.59-3.71, p<0.001) were associated with higher NRM. Karnofsky score (KS) ≤ 80 (HR vs. 90 or 100 2.07, 1.55-2.78, p<0.001) and disease status other than CP1 (HR BC vs. CP1 2.11, 1.47-3.03, p<0.001) was associated with higher RI. Higher age, lower KS, high HCT-CI, and disease status other than CP1 were associated with lower OS and PFS. In MVA, we did not observe significant differences between the SP UD, PTCy UD, and PTCy HD cohorts.


Based on our results, PTCy resulted in comparable outcomes in UD and HD allo-HCT, when compared to SP UD allo-HCT, as GRFS, PFS, NRM and OS were similar. However, there was a trend to a lower RI and higher PFS in SP UD allo-HCT which may have reached significance in a larger cohort. Furthermore, the findings of this study confirm that PTCy HD allo-HCT in CML is a valid option for patients lacking a MSD or UD. In addition, disease stage pre-transplant remains a major prognostic factor with CP1 patients having better outcomes when compared to those with more advanced phases and ≥CP1 CML. Overall, our results provide information on the efficacy of PTCy in allo-HCT for CML, and show that PTCy UD and PTCy HD are feasible allo-HCT platforms for patients diagnosed with CML.

Disclosures: Ortí: BMS, Novartis, Incyte, Pfizer: Honoraria, Speakers Bureau. Kulagin: X4 Pharmaceuticals, Alexion, Apellis, Biocad: Research Funding; Novartis, Generium, Sanofi, Roche, Johnson & Johnson, Pfizer: Speakers Bureau. Apperley: Bristol Myers Squibb, Novartis: Honoraria, Speakers Bureau; Incyte, Pfizer: Honoraria, Research Funding, Speakers Bureau. Kröger: Novartis: Research Funding; Riemser: Honoraria, Research Funding; Sanofi: Honoraria; Neovii: Honoraria, Research Funding; Jazz: Honoraria, Research Funding; Gilead/Kite: Honoraria; Celgene: Honoraria, Research Funding; AOP Pharma: Honoraria. Bloor: Kite, a Gilead Company: Honoraria; Novartis: Honoraria. Angelucci: Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Glaxo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Crispr therapeutics: Honoraria, Other: DMC; Vertex Pharmaceuticals: Honoraria, Other: DMC; Menarini-Stemline: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: steering commitee, Speakers Bureau; Blue Bird Bio: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene BSM: Honoraria, Other: DMC; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Blaise: Jazz Pharmaceuticals: Honoraria. Lopez Corral: Gilead, Novartis: Consultancy, Honoraria. Anagnostopoulos: Abbvie: Other: clinical trials; Sanofi: Other: clinical trials ; Ocopeptides: Other: clinical trials ; GSK: Other: clinical trials; Incyte: Other: clinical trials ; Takeda: Other: clinical trials ; Amgen: Other: clinical trials ; Janssen: Other: clinical trials; novartis: Other: clinical trials; Celgene: Other: clinical trials; Roche: Other: clinical trials; Astellas: Other: clinical trials . Wrobel: Janssen: Honoraria, Speakers Bureau; Roche: Honoraria, Research Funding, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Takeda: Honoraria, Speakers Bureau; BeiGene: Honoraria, Speakers Bureau. Rigacci: Merck: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accomodations, Expenses; Gilead Science: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Menarini: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Hayden: Jansen, Takeda: Other: Travel, Accomodation, Expenses; Amgen: Honoraria. Chalandon: Incyte, BMS, Pfizer, Abbie, MSD, Roche, Novartis, Amgen: Other: Advisory Board; Incyte: Speakers Bureau; Incyte, BMS, Pfizer, Abbie, MSD, Roche, Novartis, Gilead, Amgen, Jazz, Astra Zenec: Other: Travel EXpenses, Accomodation. Yakoub-Agha: Jazz Pharmaceuticals: Honoraria.

*signifies non-member of ASH